187 related articles for article (PubMed ID: 33359448)
1. The anti-tumour activity of DNA methylation inhibitor 5-aza-2'-deoxycytidine is enhanced by the common analgesic paracetamol through induction of oxidative stress.
Gleneadie HJ; Baker AH; Batis N; Bryant J; Jiang Y; Clokie SJH; Mehanna H; Garcia P; Gendoo DMA; Roberts S; Burley M; Molinolo AA; Gutkind JS; Scheven BA; Cooper PR; Parish JL; Khanim FL; Wiench M
Cancer Lett; 2021 Mar; 501():172-186. PubMed ID: 33359448
[TBL] [Abstract][Full Text] [Related]
2. 5-aza-2'-deoxycytidine induces apoptosis and inhibits tumour growth in vivo of FaDu cells, a specific HPVnegative HNSCC cell line.
Miari R; Azzam N; Bar-Shalom R; Fares F
PLoS One; 2021; 16(9):e0253756. PubMed ID: 34534222
[TBL] [Abstract][Full Text] [Related]
3. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
4. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
5. Importance of dose-schedule of 5-aza-2'-deoxycytidine for epigenetic therapy of cancer.
Lemaire M; Chabot GG; Raynal NJ; Momparler LF; Hurtubise A; Bernstein ML; Momparler RL
BMC Cancer; 2008 May; 8():128. PubMed ID: 18454857
[TBL] [Abstract][Full Text] [Related]
6. Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.
Fandy TE; Jiemjit A; Thakar M; Rhoden P; Suarez L; Gore SD
Clin Cancer Res; 2014 Mar; 20(5):1249-58. PubMed ID: 24423613
[TBL] [Abstract][Full Text] [Related]
7. Combination of azacytidine and curcumin is a potential alternative in decitabine-resistant colorectal cancer cells with attenuated deoxycytidine kinase.
Hosokawa M; Seiki R; Iwakawa S; Ogawara KI
Biochem Biophys Res Commun; 2021 Nov; 578():157-162. PubMed ID: 34571370
[TBL] [Abstract][Full Text] [Related]
8. Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells.
You L; Han Q; Zhu L; Zhu Y; Bao C; Yang C; Lei W; Qian W
Front Immunol; 2020; 11():1787. PubMed ID: 32973749
[TBL] [Abstract][Full Text] [Related]
9. Effect of cytarabine and decitabine in combination in human leukemic cell lines.
Qin T; Youssef EM; Jelinek J; Chen R; Yang AS; Garcia-Manero G; Issa JP
Clin Cancer Res; 2007 Jul; 13(14):4225-32. PubMed ID: 17634552
[TBL] [Abstract][Full Text] [Related]
10. Activation of Estrogen Receptor Alpha by Decitabine Inhibits Osteosarcoma Growth and Metastasis.
Lillo Osuna MA; Garcia-Lopez J; El Ayachi I; Fatima I; Khalid AB; Kumpati J; Slayden AV; Seagroves TN; Miranda-Carboni GA; Krum SA
Cancer Res; 2019 Mar; 79(6):1054-1068. PubMed ID: 30593524
[TBL] [Abstract][Full Text] [Related]
11. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
12. A systematic assessment of radiation dose enhancement by 5-Aza-2'-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma.
De Schutter H; Kimpe M; Isebaert S; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):904-12. PubMed ID: 19215824
[TBL] [Abstract][Full Text] [Related]
13. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
[TBL] [Abstract][Full Text] [Related]
14. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic action of decitabine (5-aza-2'-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C).
Momparler RL; Côté S; Momparler LF
Leuk Res; 2013 Aug; 37(8):980-4. PubMed ID: 23660386
[TBL] [Abstract][Full Text] [Related]
16. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
[TBL] [Abstract][Full Text] [Related]
17. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis.
Valdez BC; Li Y; Murray D; Corn P; Champlin RE; Andersson BS
Leuk Res; 2010 Mar; 34(3):364-72. PubMed ID: 19732952
[TBL] [Abstract][Full Text] [Related]
18. Low dose decitabine treatment induces CD80 expression in cancer cells and stimulates tumor specific cytotoxic T lymphocyte responses.
Wang LX; Mei ZY; Zhou JH; Yao YS; Li YH; Xu YH; Li JX; Gao XN; Zhou MH; Jiang MM; Gao L; Ding Y; Lu XC; Shi JL; Luo XF; Wang J; Wang LL; Qu C; Bai XF; Yu L
PLoS One; 2013; 8(5):e62924. PubMed ID: 23671644
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
20. Decitabine Downregulates TIGAR to Induce Apoptosis and Autophagy in Myeloid Leukemia Cells.
Li L; Liu W; Sun Q; Zhu H; Hong M; Qian S
Oxid Med Cell Longev; 2021; 2021():8877460. PubMed ID: 33532040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
